Results 31 to 40 of about 210,635 (269)

Fixed Gonadotropin-Releasing Hormone Antagonist Protocol Versus Flexible Progestin-Primed Ovarian Stimulation Protocol in Patients With Asynchronous Follicular Development During Controlled Ovulation Stimulation: A Retrospective Study

Frontiers in Endocrinology, 2021
Protocols utilizing gonadotropin-releasing hormone (GnRH) antagonists have emerged as mainstream procedures for ovarian stimulation; however, GnRH increases the risk for periodic cancellation of embryos.
Mei Dong, Li Sun, Li Huang, Fang Wang, Xiqian Zhang, Fenghua Liu   +5 more
doaj   +1 more source

ICSI cycles in women over 40 years: analysis of 3 different ovarian stimulation protocols

Middle East Fertility Society Journal, 2018
Purpose: To compare the clinical and laboratory outcomes of GnRH agonist stop, aromatase inhibitor/flexible antagonist and ultrashort flare GnRHa/flexible GnRH antagonist protocols in women (40–44) years undergoing ICSI.
H. Sibai, E.A. Elgindy, M.I. Mostafa
doaj   +1 more source

Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With “Genuine” Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF

Frontiers in Endocrinology, 2020
Objective: To examine whether the Stop GnRH-agonist combined with multiple-dose GnRH-antagonist protocol may improve conventional IVF/intracytoplasmic sperm injection (ICSI) cycle in poor ovarian response (POR) patients.Design: Cohort historical, proof ...
Raoul Orvieto, Raoul Orvieto, Michal Kirshenbaum, Valentina Galiano, Tal Elkan-Miller, Eran Zilberberg, Jigal Haas, Ravit Nahum   +7 more
doaj   +1 more source

GnRH agonist improves CLBR after one IVF cycle: a propensity score-matched and molecular mechanism study

Reproduction and Fertility
The effectiveness of the GnRH antagonist protocol remains controversial due to inconsistent conclusions and inadequate subgroup analyses. The aim of this study was to provide some references for clinicians when choosing the GnRH antagonist protocol for ...
Xueqin Cai, Hui Ding, Yi Liu, Wenqian Xiong   +3 more
doaj   +1 more source

Cumulative Live Birth Rates After the First ART Cycle Using Flexible GnRH Antagonist Protocol vs. Standard Long GnRH Agonist Protocol: A Retrospective Cohort Study in Women of Different Ages and Various Ovarian Reserve

Frontiers in Endocrinology, 2020
Objective: To compare the cumulative live birth rates (cLBRs) after the first assisted reproductive technology (ART) cycle using flexible gonadotropin releasing hormone (GnRH)-antagonist protocol vs.
Wanlin Zhang, Duo Xie, Hengde Zhang, Jianlei Huang, Xifeng Xiao, Binrong Wang, Yafei Tong, Ye Miao, Xiaohong Wang   +8 more
doaj   +1 more source

Ghrelin Decreases Firing Activity of Gonadotropin-Releasing Hormone (GnRH) Neurons in an Estrous Cycle and Endocannabinoid Signaling Dependent Manner. [PDF]

, 2013
The orexigenic peptide, ghrelin is known to influence function of GnRH neurons, however, the direct effects of the hormone upon these neurons have not been explored, yet.
Farkas, Imre, Liposits, Zsolt, Vastagh, Csaba, Sárvári, Miklós   +3 more
core  

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Pregnancy outcomes of patients with retained products of conception following miscarriage treated with relugolix, an oral gonadotropin-releasing hormone antagonist

Frontiers in Medicine
BackgroundRelugolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, represents a potentially effective and less invasive therapeutic approach for retained products of conception (RPOC).
Satoko Sasatsu, Yosuke Ono, Dai Miyashita, Tatsuya Yoshihara, Kota Tanaka, Yuri Tada, So Owada, Akiko Nakagomi, Shoko Ikeda, Maki Ohgi, Eriko Ogasahara, Hikaru Tagaya, Yasuhiko Okuda, Osamu Yoshino   +13 more
doaj   +1 more source

Severe OHSS rate of GnRH long agonist protocol versus GnRH antagonist protocol per woman.

, 2014
Severe OHSS rate of GnRH long agonist protocol versus GnRH antagonist protocol per woman.
Lin Li (28817), Dongzi Yang (468047), Wenjun Wang (314231), Qingxue Zhang (538934), Haiyan Lin (116227), Yu Li (183836)   +5 more
core   +1 more source

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer

Advanced Science, EarlyView.
Cyclin‐dependent kinase (CDK) 1 activity is a dynamic marker of treatment response in estrogen receptor positive breast cancer. Patient cohorts reveal CDK1 activity increases during progression to invasive disease, where high expression correlates with poor survival. Using a novel Cdk1 biosensor mouse alongside in vitro models, we demonstrate that CDK1
Sarah Alexandrou, Kristine J. Fernandez, Min Li Huang, Ewan K. A. Millar, Claire Vennin, Leila Eshraghi, Tan Dat Timothy Lam, Victoria Lee, Nyah C. Brooks, Janett Stoehr, Cristian Guaman Mendez, Douglas Strathdee, David Stevenson, David Herrmann, Sandra O'Toole, Paul Timpson, Max Nobis, C. Elizabeth Caldon   +17 more
wiley   +1 more source